ClinicalTrials.gg
CompletedNCT02929329GALACTIC-HFUpdated Nov 5, 2021Results posted

Registrational Study With Omecamtiv Mecarbil (AMG 423) to Treat Chronic Heart Failure With Reduced Ejection Fraction

A Phase 3 interventional study of Omecamtiv Mecarbil and Placebo in Heart Failure, sponsored by Cytokinetics. Completed at 1,034 sites in 36 countries. Open to participants aged 18 Years to 85 Years. Per ClinicalTrials.gov, last updated 2021-11-05.

Sponsored by Cytokinetics · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
8,256
Allocation
Randomized
Ages
18 Years to 85 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 14 studies testing omecamtiv mecarbil in Heart Failure — 1 open to participants now, 1 under way, 1 of them phase 3. omecamtiv mecarbil · Heart Failure.

Enrollment
Largest of 14
8,256 · median 48
Started
2017
the only one that year
Phase 3
4 of 14
1 open now
Registered
11th of 14
by date
Lead sponsor
14 of 14
Cytokinetics

Among the 14 studies testing omecamtiv mecarbil in Heart Failure, this one has the largest enrollment, is the only one that started in 2017, is one of 4 in phase 3, and was the 11th registered.

Heart Failure

6,334 studies on the registry are indexed under Heart Failure; 1,394 are open to participants now.

Browse Heart Failure studies →

Open to participants now

1 of the 14 studies testing omecamtiv mecarbil in Heart Failure is open now, in 10 countries. Recruiting first, the newest first:

By country, each count listing its studies:

About omecamtiv mecarbil

No approval found in the FDA or EMA files read. How studies give it is on its page →

Who these studies take

Of the 967 Heart Failure studies recruiting now, 690 (71%) set no upper age limit and 89 (9%) stop at 75 or younger; 63 take children under 18; 96 take healthy volunteers.

This study: 18 Years to 85 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 14 studies testing omecamtiv mecarbil in Heart Failure, or all of them as a file.
02

Study summary

The purpose of this study is to determine if treatment with omecamtiv mecarbil when added to standard of care is well tolerated and superior to placebo in reducing the risk of cardiovascular death or heart failure events in adults with chronic heart failure with reduced ejection fraction (HFrEF).

Read the detailed description

This study was conducted by Amgen as the IND holder, with Cytokinetics as a collaborator. Due to the termination of the collaboration agreement between Amgen and Cytokinetics in May 2021 and subsequent transfer of the omecamtiv mecarbil IND from Amgen to Cytokinetics, Cytokinetics is now listed as the sponsor.

03

Conditions studied

  • Heart Failure

Browse trials for

04

Who can participate

Ages eligible
18 Years to 85 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

  • Subject has provided
  • Male or female, ≥ 18 to ≤ 85 years
  • History of chronic heart failure (HF), defined as requiring treatment for HF for a minimum of 30 days before randomization
  • Left ventricle (LVEF) ≤ 35%, per subjects most recent medical record, within 12 months prior to screening.
  • (NYHA) class II to IV at most recent screening assessment.
  • Managed with HF standard of care (SoC) therapies consistent with regional clinical practice guidelines according to investigator judgment of subject's clinical status
  • Current hospitalization with primary reason of HF OR one of the following events within 1 year of screening: hospitalization with primary reason of HF; urgent visit to emergency department (ED) with primary reason of HF.
  • Elevated B-type natriuretic peptide (BNP) or n-terminal-prohormone brain natriuretic peptide (NT-proBNP)

Other Inclusion Criteria May apply

Key Exclusion Criteria:

  • Currently receiving treatment in another device or drug study, or \< 30 days since ending treatment on another investigational device or drug study(ies). Other investigational procedures while participating in this study are excluded.
  • within 5 years prior to randomization with the following exceptions: localized basal or squamous cell carcinoma of the skin, cervical intraepithelial neoplasia, stage 1 prostate carcinoma, breast ductal carcinoma in situ.
  • Subject has known sensitivity to any of the products or components to be administered during testing

Other Exclusion Criteria May apply

Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
8,256 participants (actual)

Study arms

  • Experimental
    Omecamtiv Mecarbil

    Participants received oral omecamtiv mecarbil (OM) twice daily in addition to standard heart failure therapy. The starting dose of OM was 25 mg; At week 4, participants with week 2 OM predose plasma concentrations \< 200 ng/mL had their dose increased to 50 mg BID; participants with week 2 predose plasma concentrations ≥ 200 and \< 300 ng/mL had their dose increased to 37.5 mg BID and participants with week 2 predose plasma concentrations ≥ 300 ng/mL and \< 1000 ng/mL maintained a 25 mg BID dosing regimen.

    Drug: Omecamtiv Mecarbil · Drug: Standard of Care

  • Placebo comparator
    Placebo

    Participants received matching placebo tablets twice a day in addition to standard heart failure therapy.

    Drug: Placebo · Drug: Standard of Care

Interventions

  • Omecamtiv mecarbil tablets for oral administration

    Also known as: AMG 423

  • DrugPlacebo

    Matching placebo tablets

  • DrugStandard of Care

    Participants were required to be optimally managed with standard of care therapies for chronic HF (eg, beta blockers, renin angiotensin aldosterone system inhibitors), consistent with regional clinical practice guidelines, unless contraindicated.

06

What researchers measure

Primary outcomes

  1. Time to Cardiovascular Death or First Heart Failure Event

    The primary outcome was a composite of a heart-failure (HF) event or cardiovascular (CV) death, whichever occurred first, in a time-to-event analysis. A heart-failure event was defined as an urgent clinic visit, emergency department visit, or hospitalization for subjectively and objectively worsening heart failure leading to treatment intensification beyond a change in oral diuretic therapy. All deaths and HF events were adjudicated by an independent external clinical events committee (CEC) at the Duke Clinical Research Institute, using standardized definitions based on the recent American College of Cardiology/American Heart Association (ACC/AHA) standards for endpoint definitions in cardiovascular clinical trials. Time to cardiovascular death or first HF event was analyzed using Kaplan-Meier (KM) methods. Since the median was not calculated, the percentage of participants with a positively adjudicated event during the study is reported.

    Time frame: From randomization to up to earliest of last confirmed survival status date or analysis cut-off date (07 August 2020); the overall median duration of follow-up was 21.8 months up to a maximum of 42 months.

Secondary outcomes

  1. Time to Cardiovascular Death

    Cardiovascular death includes acute myocardial infarction (MI), sudden cardiac death, death due to heart failure, death due to stroke, death due to cardiovascular (CV) procedures, death due to CV hemorrhage, and death due to other CV causes. All deaths were adjudicated by an independent external clinical-events committee at the Duke Clinical Research Institute, using standardized definitions based on the recent ACC/AHA standards for endpoint definitions in cardiovascular clinical trials. Time to cardiovascular death was analyzed using Kaplan-Meier methods. Since the median was not calculated, the percentage of participants with a positively adjudicated event during the study is reported.

    Time frame: From randomization to up to earliest of last confirmed survival status date or analysis cut-off date (07 August 2020); the overall median duration of follow-up was 21.8 months up to a maximum of 42 months.

  2. Change From Baseline in Kansas City Cardiomyopathy Questionnaire Total Symptom Score (KCCQ TSS) at Week 24

    The Kansas City Cardiomyopathy Questionnaire is a self-administered questionnaire with a 2-week recall period that includes 23 items that map to 7 domains: symptom frequency; symptom burden; symptom stability; physical limitations; social limitations; quality of life; and self-efficacy (the patient's understanding of how to manage their heart failure). The symptom frequency and symptom burden domains are merged into a total symptom score. Scores are represented on a 0-to-100-point scale, where lower scores represent more frequent and severe symptoms and scores of 100 indicate no symptoms. The change from baseline in KCCQ TSS was analyzed separately for each randomization setting (inpatient and outpatient). Least squares means are from the mixed model which includes baseline total symptom score value, region, baseline eGFR, scheduled visit, treatment group and interaction of treatment with scheduled visit as covariates.

    Time frame: Baseline and Week 24

  3. Time to First Heart Failure Hospitalization

    A HF hospitalization is defined as an event that met all of the following criteria: 1. The participant was admitted to the hospital with a primary diagnosis of HF; 2. The length of stay in the hospital extended for at least 24 hours; 3. The participant exhibited documented new or worsening symptoms due to HF on presentation; 4. The participant had objective evidence of new or worsening HF; 5. The participant received initiation or intensification of treatment specifically for HF, including an intravenous diuretic or vasoactive agent, mechanical or surgical intervention, or mechanical fluid removal. Events were adjudicated by an independent external CEC at the Duke Clinical Research Institute using standardized definitions based on the ACC/AHA standards for endpoint definitions in CV clinical trials. Time to first HF hospitalization was analyzed using KM methods. Since the median was not calculated, the percentage of participants with a positively adjudicated event is reported.

    Time frame: From randomization to up to earliest of last confirmed survival status date or analysis cut-off date (07 August 2020); the overall median duration of follow-up was 21.8 months up to a maximum of 42 months.

  4. Time to All-cause Death

    All events were adjudicated by an independent external clinical-events committee at the Duke Clinical Research Institute, using standardized definitions based on the recent ACC/AHA standards for endpoint definitions in cardiovascular clinical trials. Time to all-cause death was analyzed using Kaplan-Meier methods. Since the median was not calculated, the percentage of participants with an event are reported. Events that occurred up to the earliest of last confirmed survival status date or analysis cut-off date (07 August 2020) are included.

    Time frame: From randomization up to earliest of last confirmed survival status date or analysis cut-off date (07 August 2020); the overall median duration of follow-up was 21.8 months up to a maximum of 42 months.

07

Results

Posted Jul 20, 2021

Participant flow

A total of 11,121 patients underwent screening at 944 sites in 35 countries. Of these patients, 8,256 were randomized, but 24 patients from one site were excluded because of Good Clinical Practice violations and are not included in the data reported below.

Participant flow — Overall Study
MilestonePlaceboOmecamtiv Mecarbil
Started41124120
Received treatment41014110
Completed30083028
Not completed11041092
Withdrew: Withdrawal by subject2421
Withdrew: Lost to follow-up2620
Withdrew: Death10541051

Outcome measures

PrimaryTime to Cardiovascular Death or First Heart Failure Event

The primary outcome was a composite of a heart-failure (HF) event or cardiovascular (CV) death, whichever occurred first, in a time-to-event analysis. A heart-failure event was defined as an urgent clinic visit, emergency department visit, or hospitalization for subjectively and objectively worsening heart failure leading to treatment intensification beyond a change in oral diuretic therapy. All deaths and HF events were adjudicated by an independent external clinical events committee (CEC) at the Duke Clinical Research Institute, using standardized definitions based on the recent American College of Cardiology/American Heart Association (ACC/AHA) standards for endpoint definitions in cardiovascular clinical trials. Time to cardiovascular death or first HF event was analyzed using Kaplan-Meier (KM) methods. Since the median was not calculated, the percentage of participants with a positively adjudicated event during the study is reported.

Time frame:
From randomization to up to earliest of last confirmed survival status date or analysis cut-off date (07 August 2020); the overall median duration of follow-up was 21.8 months up to a maximum of 42 months.
Reported as:
Number · percentage of participants
Time to Cardiovascular Death or First Heart Failure Event
percentage of participantsPlaceboOmecamtiv Mecarbil
Time to Cardiovascular Death or First Heart Failure Event39.137.0
Statistical analysis
  • Placebo vs Omecamtiv Mecarbil · Regression, Cox · p = 0.0252 · Hazard ratio (hr): 0.92 · 95% CI 0.86 to 0.99Cox proportional-hazards model with baseline hazards stratified according to the randomization setting and geographic region and with the treatment group and baseline eGFR as covariates.
  • Placebo vs Omecamtiv Mecarbil · Stratified log-rank test · p = 0.0211Log-rank test stratified by randomization setting and region.
  • Placebo vs Omecamtiv Mecarbil · Hazard ratio (hr): 0.92 · 95% CI 0.86 to 0.99Cox proportional-hazards model with baseline hazards stratified according to the randomization setting and geographic region and with the treatment group and baseline eGFR as covariates.
SecondaryTime to Cardiovascular Death

Cardiovascular death includes acute myocardial infarction (MI), sudden cardiac death, death due to heart failure, death due to stroke, death due to cardiovascular (CV) procedures, death due to CV hemorrhage, and death due to other CV causes. All deaths were adjudicated by an independent external clinical-events committee at the Duke Clinical Research Institute, using standardized definitions based on the recent ACC/AHA standards for endpoint definitions in cardiovascular clinical trials. Time to cardiovascular death was analyzed using Kaplan-Meier methods. Since the median was not calculated, the percentage of participants with a positively adjudicated event during the study is reported.

Time frame:
From randomization to up to earliest of last confirmed survival status date or analysis cut-off date (07 August 2020); the overall median duration of follow-up was 21.8 months up to a maximum of 42 months.
Reported as:
Number · percentage of participants
Time to Cardiovascular Death
percentage of participantsPlaceboOmecamtiv Mecarbil
Time to Cardiovascular Death19.419.6
Statistical analysis
  • Placebo vs Omecamtiv Mecarbil · Regression, Cox · p = 0.8555 (If significance for the primary outcome was determined, cardiovascular death was tested against an alpha of 0.048.) · Hazard ratio (hr): 1.01 · 95% CI 0.92 to 1.11Cox proportional-hazards model with baseline hazards stratified according to the randomization setting and geographic region and with the treatment group and baseline eGFR as covariates.
  • Placebo vs Omecamtiv Mecarbil · Hazard ratio (hr): 1.01 · 95% CI 0.92 to 1.11Cox proportional-hazards model with baseline hazards stratified according to the randomization setting and geographic region and with the treatment group and baseline eGFR as covariates.
SecondaryChange From Baseline in Kansas City Cardiomyopathy Questionnaire Total Symptom Score (KCCQ TSS) at Week 24

The Kansas City Cardiomyopathy Questionnaire is a self-administered questionnaire with a 2-week recall period that includes 23 items that map to 7 domains: symptom frequency; symptom burden; symptom stability; physical limitations; social limitations; quality of life; and self-efficacy (the patient's understanding of how to manage their heart failure). The symptom frequency and symptom burden domains are merged into a total symptom score. Scores are represented on a 0-to-100-point scale, where lower scores represent more frequent and severe symptoms and scores of 100 indicate no symptoms. The change from baseline in KCCQ TSS was analyzed separately for each randomization setting (inpatient and outpatient). Least squares means are from the mixed model which includes baseline total symptom score value, region, baseline eGFR, scheduled visit, treatment group and interaction of treatment with scheduled visit as covariates.

Time frame:
Baseline and Week 24
Reported as:
Least squares mean · scores on a scale
Change From Baseline in Kansas City Cardiomyopathy Questionnaire Total Symptom Score (KCCQ TSS) at Week 24
scores on a scalePlacebo: OupatientsOmecamtiv Mecarbil: OutpatientsPlacebo: InpatientsOmecamtiv Mecarbil: Inpatients
Change From Baseline in Kansas City Cardiomyopathy Questionnaire Total Symptom Score (KCCQ TSS) at Week 246.29 ± 0.345.83 ± 0.3421.15 ± 0.7123.65 ± 0.70
Statistical analysis
  • Placebo: Oupatients vs Omecamtiv Mecarbil: Outpatients · Least squares (ls) mean difference: -0.46 · 95% CI -1.40 to 0.48Treatment difference = Omecamtiv mecarbil - Placebo
  • Placebo: Inpatients vs Omecamtiv Mecarbil: Inpatients · Ls mean difference: 2.50 · 95% CI 0.54 to 4.46Treatment difference = Omecamtiv mecarbil - Placebo
  • Placebo: Oupatients vs Omecamtiv Mecarbil: Outpatients vs Placebo: Inpatients vs Omecamtiv Mecarbil: Inpatients · Omnibus F-test · p = 0.0278
  • Placebo: Oupatients vs Omecamtiv Mecarbil: Outpatients vs Placebo: Inpatients vs Omecamtiv Mecarbil: Inpatients · Pooled treatment difference: 0.75 · 95% CI -2.55 to 4.51Overall pooled estimate of treatment difference (Omecamtiv mecarbil - Placebo) using random effects meta-analysis approach.
  • Placebo: Oupatients vs Omecamtiv Mecarbil: Outpatients · Ls mean difference: -0.71 · 95% CI -1.62 to 0.20Treatment difference = Omecamtiv mecarbil - Placebo
  • Placebo: Inpatients vs Omecamtiv Mecarbil: Inpatients · Ls mean difference: 2.31 · 95% CI 0.80 to 3.82Treatment difference = Omecamtiv mecarbil - Placebo
SecondaryTime to First Heart Failure Hospitalization

A HF hospitalization is defined as an event that met all of the following criteria: 1. The participant was admitted to the hospital with a primary diagnosis of HF; 2. The length of stay in the hospital extended for at least 24 hours; 3. The participant exhibited documented new or worsening symptoms due to HF on presentation; 4. The participant had objective evidence of new or worsening HF; 5. The participant received initiation or intensification of treatment specifically for HF, including an intravenous diuretic or vasoactive agent, mechanical or surgical intervention, or mechanical fluid removal. Events were adjudicated by an independent external CEC at the Duke Clinical Research Institute using standardized definitions based on the ACC/AHA standards for endpoint definitions in CV clinical trials. Time to first HF hospitalization was analyzed using KM methods. Since the median was not calculated, the percentage of participants with a positively adjudicated event is reported.

Time frame:
From randomization to up to earliest of last confirmed survival status date or analysis cut-off date (07 August 2020); the overall median duration of follow-up was 21.8 months up to a maximum of 42 months.
Reported as:
Number · percentage of participants
Time to First Heart Failure Hospitalization
percentage of participantsPlaceboOmecamtiv Mecarbil
Time to First Heart Failure Hospitalization28.727.7
Statistical analysis
  • Placebo vs Omecamtiv Mecarbil · Regression, Cox · p = 0.1902 (If statistical significance was achieved for both the time to CV death and change from baseline in the KCCQ TSS, time to first heart failure hospitalization was to be tested at the full alpha.) · Hazard ratio (hr): 0.95 · 95% CI 0.87 to 1.03Cox proportional-hazards model with baseline hazards stratified according to the randomization setting and geographic region and with the trial group and the baseline eGFR as covariates.
  • Placebo vs Omecamtiv Mecarbil · Hazard ratio (hr): 0.96 · 95% CI 0.88 to 1.04Cox proportional-hazards model with baseline hazards stratified according to the randomization setting and geographic region and with the trial group and the baseline eGFR as covariates.
SecondaryTime to All-cause Death

All events were adjudicated by an independent external clinical-events committee at the Duke Clinical Research Institute, using standardized definitions based on the recent ACC/AHA standards for endpoint definitions in cardiovascular clinical trials. Time to all-cause death was analyzed using Kaplan-Meier methods. Since the median was not calculated, the percentage of participants with an event are reported. Events that occurred up to the earliest of last confirmed survival status date or analysis cut-off date (07 August 2020) are included.

Time frame:
From randomization up to earliest of last confirmed survival status date or analysis cut-off date (07 August 2020); the overall median duration of follow-up was 21.8 months up to a maximum of 42 months.
Reported as:
Number · percentage of participants
Time to All-cause Death
percentage of participantsPlaceboOmecamtiv Mecarbil
Time to All-cause Death25.925.9
Statistical analysis
  • Placebo vs Omecamtiv Mecarbil · Regression, Cox · p = 0.9633 (If time to first heart failure hospitalization was statistically significant, time to all-cause death was to be tested with the same alpha as time to first heart failure hospitalization.) · Hazard ratio (hr): 1.00 · 95% CI 0.92 to 1.09Cox proportional-hazards model with baseline hazards stratified according to the randomization setting and geographic region and with the trial group and the baseline eGFR as covariates.

Adverse events

Collected over All-cause mortality is reported from randomization until end of study (27 August 2020); median (min, max) time on study was 21.8 (0, 42) months. Adverse events are reported from first dose of study drug until 30 days after last dose; median (min, max) treatment duration was 19.5 (0, 42) months.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Placebo1,078/4,112 (26.2%)2,435/4,101 (59.4%)1,146/4,101 (27.9%)
Omecamtiv Mecarbil1,078/4,120 (26.2%)2,373/4,110 (57.7%)1,129/4,110 (27.5%)
Most frequent serious events
Showing 10 of 1,190
Most frequent serious events
EventPlaceboOmecamtiv Mecarbil
Cardiac failureCardiac disorders1045/4101988/4110
Cardiac failure acuteCardiac disorders251/4101212/4110
PneumoniaInfections and infestations179/4101171/4110
Cardiac failure chronicCardiac disorders170/4101156/4110
Cardiac failure congestiveCardiac disorders154/4101147/4110
Acute kidney injuryRenal and urinary disorders138/4101129/4110
Ventricular tachycardiaCardiac disorders129/4101106/4110
Atrial fibrillationCardiac disorders113/410194/4110
Cardiogenic shockCardiac disorders68/410175/4110
Acute myocardial infarctionCardiac disorders64/410171/4110
Most frequent other events
Most frequent other events
EventPlaceboOmecamtiv Mecarbil
Cardiac failureCardiac disorders291/4101268/4110
HypotensionVascular disorders242/4101276/4110
DyspnoeaRespiratory, thoracic and mediastinal disorders258/4101249/4110
DizzinessNervous system disorders183/4101232/4110
HypertensionVascular disorders222/4101190/4110
HyperkalaemiaMetabolism and nutrition disorders213/4101202/4110

Baseline characteristics

The full analysis set included all the randomized participants except for 24 patients from a single site who were excluded on the basis of Good Clinical Practice violations.

Age, Continuous
Age, Continuous(years)PlaceboOmecamtiv MecarbilTotal
Mean64.5 ± 11.464.5 ± 11.364.5 ± 11.4
Age, Customized
Age, Customized(Participants)PlaceboOmecamtiv MecarbilTotal
18 to 64 years187318743747
65 to 84 years221122204431
85 years and over282654
Sex: Female, Male
Sex: Female, Male(Participants)PlaceboOmecamtiv MecarbilTotal
Female8748751749
Male323832456483
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)PlaceboOmecamtiv MecarbilTotal
Hispanic or Latino8858861771
Not Hispanic or Latino322732346461
Unknown or Not Reported000
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)PlaceboOmecamtiv MecarbilTotal
American Indian or Alaska Native383573
Asian355355710
Black or African American277285562
Multiple9699195
Native Hawaiian or Other Pacific Islander6713
White320131966397
Other139143282
Randomization Setting
Randomization Setting(Participants)PlaceboOmecamtiv MecarbilTotal
Currently hospitalized for heart failure105010512101
Recently and not currently hospitalized for heart failure306230696131
Region
Region(Participants)PlaceboOmecamtiv MecarbilTotal
United States and Canada6936931386
Latin America7877871574
Western Europe, South Africa, and Australasia9609611921
Eastern Europe including Russia133713442681
Asia335335670
08

Study locations

1,034 sites
  • Research Site
    Birmingham, Alabama 35233, United States
  • Research Site
    Birmingham, Alabama 35243, United States
  • Research Site
    Birmingham, Alabama 35294, United States
  • Research Site
    Fort Payne, Alabama 35967, United States
  • Research Site
    Huntsville, Alabama 35801, United States
  • Research Site
    Mobile, Alabama 36608, United States
  • Research Site
    Scottsboro, Alabama 35768, United States
  • Research Site
    Tuscumbia, Alabama 35674, United States
  • Research Site
    Gilbert, Arizona 85297, United States
  • Research Site
    Phoenix, Arizona 85032, United States
  • Research Site
    Tucson, Arizona 85710, United States
  • Research Site
    Tucson, Arizona 85724, United States
  • Research Site
    Jonesboro, Arkansas 72401, United States
  • Research Site
    Little Rock, Arkansas 72205, United States
  • Research Site
    Anaheim, California 92801, United States
  • Research Site
    Beverly Hills, California 90211, United States
  • Research Site
    Burbank, California 91505, United States
  • Research Site
    Carmichael, California 95608, United States
  • Research Site
    Fresno, California 93701, United States
  • Research Site
    Huntington Beach, California 92648, United States
  • Research Site
    Loma Linda, California 92357, United States
  • Research Site
    Long Beach, California 90806, United States
  • Research Site
    Long Beach, California 90822, United States
  • Research Site
    Los Alamitos, California 90720, United States
  • Research Site
    Los Angeles, California 90033, United States
  • Research Site
    Los Angeles, California 90073, United States
  • Research Site
    Mission Viejo, California 92691, United States
  • Research Site
    Newport Beach, California 92663, United States
  • Research Site
    Northridge, California 91325, United States
  • Research Site
    Redondo Beach, California 90277, United States
  • Research Site
    Riverside, California 92506, United States
  • Research Site
    Sacramento, California 95819, United States
  • Research Site
    San Francisco, California 94115, United States
  • Research Site
    San Pedro, California 90732, United States
  • Research Site
    Santa Ana, California 92704, United States
  • Research Site
    Santa Rosa, California 95405, United States
  • Research Site
    Stanford, California 94305, United States
  • Research Site
    Stockton, California 95204, United States
  • Research Site
    Torrance, California 90502, United States
  • Research Site
    Torrance, California 90503, United States
  • Research Site
    Tustin, California 92780, United States
  • Research Site
    Ventura, California 93003, United States
  • Research Site
    Aurora, Colorado 80045, United States
  • Research Site
    Colorado Springs, Colorado 80909, United States
  • Research Site
    Denver, Colorado 80204, United States
  • Research Site
    Denver, Colorado 80218, United States
  • Research Site
    Littleton, Colorado 80120, United States
  • Research Site
    Wheat Ridge, Colorado 80033, United States
  • Research Site
    Hartford, Connecticut 06102, United States
  • Research Site
    Stamford, Connecticut 06905, United States
  • Research Site
    Waterbury, Connecticut 06708, United States
  • Research Site
    West Haven, Connecticut 06516, United States
  • Research Site
    Newark, Delaware 19718, United States
  • Research Site
    Washington, District of Columbia 20010, United States
  • Research Site
    Washington, District of Columbia 20037, United States
  • Research Site
    Washington, District of Columbia 20422, United States
  • Research Site
    Altamonte Springs, Florida 32714, United States
  • Research Site
    Aventura, Florida 33180, United States
  • Research Site
    Bay Pines, Florida 33744, United States
  • Research Site
    Boynton Beach, Florida 33472, United States
  • Research Site
    Crystal River, Florida 34429, United States
  • Research Site
    Daytona Beach, Florida 32117, United States
  • Research Site
    Doral, Florida 33126, United States
  • Research Site
    Gainesville, Florida 32608, United States
  • Research Site
    Hialeah, Florida 33012, United States
  • Research Site
    Hialeah, Florida 33013, United States
  • Research Site
    Inverness, Florida 34452, United States
  • Research Site
    Jacksonville, Florida 32209, United States
  • Research Site
    Jacksonville, Florida 32216, United States
  • Research Site
    Miami Beach, Florida 33140, United States
  • Research Site
    Miami, Florida 33032, United States
  • Research Site
    Miami, Florida 33125, United States
  • Research Site
    Miami, Florida 33126, United States
  • Research Site
    Miami, Florida 33136, United States
  • Research Site
    Miami, Florida 33144, United States
  • Research Site
    Miami, Florida 33145, United States
  • Research Site
    Miami, Florida 33147, United States
  • Research Site
    Miami, Florida 33165, United States
  • Research Site
    Miami, Florida 33166, United States
  • Research Site
    Miami, Florida 33174, United States
  • Research Site
    Naples, Florida 34102, United States
  • Research Site
    Ocala, Florida 34471, United States
  • Research Site
    Palm Harbor, Florida 34684, United States
  • Research Site
    Pembroke Pines, Florida 33028, United States
  • Research Site
    Sarasota, Florida 34232, United States
  • Research Site
    Tampa, Florida 33613, United States
  • Research Site
    Zephyrhills, Florida 33541, United States
  • Research Site
    Athens, Georgia 30606, United States
  • Research Site
    Atlanta, Georgia 30303, United States
  • Research Site
    Atlanta, Georgia 30309, United States
  • Research Site
    Augusta, Georgia 30909, United States
  • Research Site
    Columbus, Georgia 31904, United States
  • Research Site
    Smyrna, Georgia 30082, United States
  • Research Site
    Woodstock, Georgia 30189, United States
  • Research Site
    'Aiea, Hawaii 96701, United States
  • Research Site
    Honolulu, Hawaii 96813, United States
  • Research Site
    Arlington Heights, Illinois 60005, United States
  • Research Site
    Champaign, Illinois 61820, United States
  • Research Site
    Chicago, Illinois 60612, United States
  • Research Site
    Fairview Heights, Illinois 62208, United States

Showing the first 100 of 1,034 sites across 36 countries. Choose a country and city above to see the rest.

09

References and documents

Publications

  • Teerlink JR, Diaz R, Felker GM, McMurray JJV, Metra M, Solomon SD, Biering-Sorensen T, Bohm M, Bonderman D, Fang JC, Lanfear DE, Lund M, Momomura SI, O'Meara E, Ponikowski P, Spinar J, Flores-Arredondo JH, Claggett BL, Heitner SB, Kupfer S, Abbasi SA, Malik FI; GALACTIC-HF Investigators. Effect of Ejection Fraction on Clinical Outcomes in Patients Treated With Omecamtiv Mecarbil in GALACTIC-HF. J Am Coll Cardiol. 2021 Jul 13;78(2):97-108. doi: 10.1016/j.jacc.2021.04.065. Epub 2021 May 17. PubMed 34015475 ↗
  • Solomon SD, Claggett BL, Miao ZM, Diaz R, Felker GM, McMurray JJV, Metra M, Corbalan R, Filippatos G, Goudev AR, Mareev V, Serpytis P, Suter T, Yilmaz MB, Zannad F, Kupfer S, Heitner SB, Malik FI, Teerlink JR. Influence of atrial fibrillation on efficacy and safety of omecamtiv mecarbil in heart failure: the GALACTIC-HF trial. Eur Heart J. 2022 Jun 14;43(23):2212-2220. doi: 10.1093/eurheartj/ehac144. Erratum In: Eur Heart J. 2022 Aug 7;43(30):2903. doi: 10.1093/eurheartj/ehac332. PubMed 35325102 ↗
  • Felker GM, Solomon SD, Claggett B, Diaz R, McMurray JJV, Metra M, Anand I, Crespo-Leiro MG, Dahlstrom U, Goncalvesova E, Howlett JG, MacDonald P, Parkhomenko A, Tomcsanyi J, Abbasi SA, Heitner SB, Hucko T, Kupfer S, Malik FI, Teerlink JR. Assessment of Omecamtiv Mecarbil for the Treatment of Patients With Severe Heart Failure: A Post Hoc Analysis of Data From the GALACTIC-HF Randomized Clinical Trial. JAMA Cardiol. 2022 Jan 1;7(1):26-34. doi: 10.1001/jamacardio.2021.4027. PubMed 34643642 ↗
  • Teerlink JR, Diaz R, Felker GM, McMurray JJV, Metra M, Solomon SD, Adams KF, Anand I, Arias-Mendoza A, Biering-Sorensen T, Bohm M, Bonderman D, Cleland JGF, Corbalan R, Crespo-Leiro MG, Dahlstrom U, Echeverria LE, Fang JC, Filippatos G, Fonseca C, Goncalvesova E, Goudev AR, Howlett JG, Lanfear DE, Li J, Lund M, Macdonald P, Mareev V, Momomura SI, O'Meara E, Parkhomenko A, Ponikowski P, Ramires FJA, Serpytis P, Sliwa K, Spinar J, Suter TM, Tomcsanyi J, Vandekerckhove H, Vinereanu D, Voors AA, Yilmaz MB, Zannad F, Sharpsten L, Legg JC, Varin C, Honarpour N, Abbasi SA, Malik FI, Kurtz CE; GALACTIC-HF Investigators. Cardiac Myosin Activation with Omecamtiv Mecarbil in Systolic Heart Failure. N Engl J Med. 2021 Jan 14;384(2):105-116. doi: 10.1056/NEJMoa2025797. Epub 2020 Nov 13. PubMed 33185990 ↗
  • Teerlink JR, Diaz R, Felker GM, McMurray JJV, Metra M, Solomon SD, Legg JC, Buchele G, Varin C, Kurtz CE, Malik FI, Honarpour N. Omecamtiv Mecarbil in Chronic Heart Failure With Reduced Ejection Fraction: Rationale and Design of GALACTIC-HF. JACC Heart Fail. 2020 Apr;8(4):329-340. doi: 10.1016/j.jchf.2019.12.001. Epub 2020 Feb 6. PubMed 32035892 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — De-identified individual patient data for variables necessary to address the specific research question in an approved data sharing request

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report

Time frame: Data sharing requests relating to this study will be considered beginning 18 months after the study has ended and either 1) the product and indication (or other new use) have been granted marketing authorization in both the US and Europe or 2) clinical development for the product and/or indication discontinues and the data will not be submitted to regulatory authorities. There is no end date for eligibility to submit a data sharing request for this study.

Access criteria: Qualified researchers may submit a request containing the research objectives, the Amgen product(s) and Amgen study/studies in scope, endpoints/outcomes of interest, statistical analysis plan, data requirements, publication plan, and qualifications of the researcher(s). In general, Amgen does not grant external requests for individual patient data for the purpose of re-evaluating safety and efficacy issues already addressed in the product labelling. Requests are reviewed by a committee of internal advisors, and if not approved, may be further arbitrated by a Data Sharing Independent Review Panel. Upon approval, information necessary to address the research question will be provided under the terms of a data sharing agreement. This may include anonymized individual patient data and/or available supporting documents, containing fragments of analysis code where provided in analysis specifications. Further details are available at the URL below.

Data sharing details ↗ · www.amgen.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jan 2017 to primary completion in Sep 2020, 44 months.

Results were first posted in Jul 2021, 10 months after primary completion.

Of 63 industry-sponsored phase 3 interventional studies under Heart Failure, half reached primary completion within 36 months of starting (the median), counting those still running; a quarter within 20 and three quarters within 44. This study's 44 months is above that.

Counting every sponsor, half of 150 studies reached it within 39 months; a quarter within 26 and three quarters within 57.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 30, 2016
First posted
Oct 11, 2016
StartActual
Jan 6, 2017
Primary completionActual
Sep 14, 2020
CompletionActual
Sep 14, 2020
Results first posted
Jul 20, 2021
Last update
Nov 5, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 5, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02929329
Lead sponsor
Cytokinetics
Responsible party
Sponsor
First posted
Oct 11, 2016
Start date
Jan 6, 2017
Primary completion
Sep 14, 2020
Completion
Sep 14, 2020
Results posted
Jul 20, 2021
Last update
Nov 5, 2021

Study contacts

MD
study director · Amgen

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Omecamtiv mecarbil

Start the discussion